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The toothless (tl) mutation in the rat is a naturally occurring,
autosomal recessive mutation resulting in a profound deficiency of
bone-resorbing osteoclasts and peritoneal macrophages. The fail-
ure to resorb bone produces severe, unrelenting osteopetrosis,
with a highly sclerotic skeleton, lack of marrow spaces, failure of
tooth eruption, and other pathologies. Injections of CSF-1 improve
some, but not all, of these. In this report we have used polymor-
phism mapping, sequencing, and expression studies to identify the
genetic lesion in the tl rat. We found a 10-base insertion near the
beginning of the open reading of the Csf1 gene that yields a
truncated, nonfunctional protein and an early stop codon, thus
rendering the tl rat CSF-1null. All mutants were homozygous for the
mutation and all carriers were heterozygous. No CSF-1 transcripts
were identified in rat mRNA that would avoid the mutation via
alternative splicing. The biology and actions of CSF-1 have been
elucidated by many studies that use another naturally occurring
mutation, the op mouse, in which a single base insertion also
disrupts the reading frame. The op mouse has milder osteoclas-
topenia and osteopetrosis than the tl rat and recovers spontane-
ously over the first few months of life. Thus, the tl rat provides a
second model in which the functions of CSF-1 can be studied.
Understanding the similarities and differences in the phenotypes
of these two models will be important to advancing our knowl-
edge of the many actions of CSF-1.
Osteoclasts, multinucleated cells that resorb bone, differen-tiate via fusion of mononuclear precursors of the mono-
cytemacrophage lineage, in large part under the local control of
factors secreted by bone-forming osteoblasts (1). Insights into
factors that regulate the formation and activation of osteoclasts
have come from naturally occurring mutations and genetic
manipulations that cause osteopetrosis, a condition in which
defective bone resorption leads to a sclerotic skeleton (2). One
such factor is the cytokine CSF-1 (M-CSF), originally identified
as a monocyte-macrophage colony-stimulating factor (3). Iden-
tification of a frameshift mutation in the Csf1 gene of the
osteopetrosis (op) mouse was a major step in understanding
osteoclast ontogeny (4). (The op mutation in the mouse, which
affects an osteoblast signal, is not to be confused with the op
mutation in the rat, a severe, naturally occurring osteopetrotic
mutation that affects osteoclast function.) Since then, many
genes have been identified that do double-duty in the immune
and skeletal systems. Tumor necrosis factor superfamily member
11 [TNFSF11, also called TRANCE (5), RANKL (6), ODF (7),
and OPGL (8)], its receptor (RANK), and the receptor-
associated intracellular signal initiator (TRAF6) are essential for
lymph node organogenesis, maintaining antigen presenting den-
dritic cells, and formation of osteoclasts (refs. 9–12; reviewed in
ref. 13). The transcription factor PU.1 functions in osteoclast
differentiation and activation and in myeloid cells and B lym-
phocytes (14); and NF-B, originally described as regulating
transcription of Ig light chain genes, is likewise necessary for
osteoclastogenesis (15).
Phenotypes of osteopetrotic mutations vary widely, depending
on where bone resorption is intercepted. Most of the proteins
listed above act in the osteoclast or its precursors; however, two
key factors that promote osteoclast differentiation and activation
in vivo, CSF-1 and TNFSF11, are supplied by osteoblasts. These
two are also necessary and sufficient to induce mononuclear
precursors to fuse and differentiate into active, bone resorbing
cells in vitro (16–18). One osteopetrotic mutation in the rat,
toothless (tl), is due to the loss of such an osteoblast-derived,
osteoclast-inducing signal, as demonstrated both in vivo and in
vitro. In coculture experiments, tl osteoblasts cannot activate
normal osteoclasts (19, 20), and the defect is not cell autonomous
for the osteoclast lineage, because transplanting normal bone
marrow or spleen-derived osteoclast precursors fails to improve
tl rats (21). The tl rat is a naturally occurring, autosomal recessive
mutation identified in 1974 (22). It exhibits severe, unremitting
osteoclastopenia and a host of other pathologies. If phenotype
is used as a guide to select candidate genes, the skeletal
phenotype of tl rats resembles TNFSF11null mice more than it
does op (CSF-1 frame-shifted) mice. op mice have milder
osteopetrosis and osteoclastopenia and recover in the first few
postnatal months (23). TNFSF11null mice and tl rats also share
severe and progressive growth plate chondrodystrophy not seen
in most other osteopetrotic mutations (9, 10, 24, 25). Despite the
striking phenotypic similarities between tl rats and TNFSF11null
mice, we recently showed that this was not the locus of the tl
mutation (26). We therefore undertook investigations to map the
tl locus by positional cloning using polymorphic markers in the
rat genome. Mapping and sequencing results revealed the pres-
ence of a CSF-1 frameshift mutation in the tl rat, thus rendering
it a Csf1null mutant.
Materials and Methods
Animals. tl mutants were obtained from the inbred colony main-
tained at the University of Massachusetts Medical School. The
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colony, which is on the Fischer background, was rederived in
1997 and has been kept under SPF conditions. All procedures
were in accordance with the Guide for the Care and Use of
Laboratory Animals, National Institutes of Health, and ap-
proved by the Institutional Animal Care and Use Committee.
Female breeders of the Brown Norway (BN)SSN strain were
from Harlan Breeders (Indianapolis). Preliminary tests showed
that many microsatellite markers are informative between the
BNSSN and tl strains. Diagnosis of osteopetrosis was done by
neonatal x-ray (27), which shows the mutants to lack marrow
cavities. Mature tl males (i.e., homozygous mutants) were bred
with BNSSN females to produce the obligate heterozygous F1
generation. F1 animals were then intercrossed to produce the F2
generation.
Mapping the tl Mutation. Genomic DNA was obtained from tail
biopsies of 11 F2 mutants and used to map the chromosomal
region carrying the tl mutation. Markers, from the Rat MapPairs
screening set (Research Genetics, Huntsville, AL), were ana-
lyzed by PCR using radioactively labeled primers. After elec-
trophoresis on polyacrylamide gels, PCR products were visual-
ized by autoradiography. Additional markers were selected
from the map based on the MIT (SHRSP  BN) F2 cross
(www.rgd.mcw.edu).
RT-PCR and Cloning of Normal and tl Rat CSF-1 cDNA. Total RNA was
isolated from rat tissues by using TRIzol reagent according to
the manufacturer’s instructions (GIBCOBRL). cDNA was
synthesized by reverse transcription of 5 g of total RNA with
an oligo(dT) primer (SuperScript, GIBCOBRL). cDNA prod-
ucts were used as templates for PCR amplification with primers
flanking different regions of the ORF based on the published rat
cDNA (ref. 28; accession no. NM023981), and the PCR prod-
ucts were cloned into the TOPO 2.1 vector (Invitrogen) and
sequenced as described (29).
Characterization of Normal Rat CSF-1 Genomic DNA. PCR primers
sets were designed based on a published rat CSF-1 sequence (ref.
28; accession no. NM023981) that encompassed the entire
ORF. PCR products were purified with the Rapid PCR system
(CLONTECH) and sequenced using Big Dye Terminator Cycle
Sequencing (PE Applied Biosystems). Fragments were analyzed
on an ABI 3100 automated sequencer. During the course of
these investigations, our sequence was found to differ at various
positions from the database sequence (see Results). We found
that the previously reported sequence for rat CSF-1 is 100%
identical to the mouse sequence and is thus a misidentified
mouse cDNA sequence. The rat Csf1 sequence was determined
both on cDNA and genomic DNA samples. PCR reactions using
primers that bridge introns were performed to analyze the
exonintron structure of the rat Csf1 gene.
Identification of the tl Mutation. Direct sequence analysis was
performed on both genomic DNA and RT-PCR products from
tl rats. Once the mutation was identified, we determined the
genotype of animals by using PCR primers that flank the
mutation. PCR conditions: forward primer, 5-GTTTGCCTCG-
GTGCTCTCGG-3; reverse primer, 5-GAAGAAGGGCAG-
CGCCCCG-3; anneal at 60°C, 50 s; elongate at 72°C, 90 s;
denature at 95°C, 50 s; 30 cycles. This results in a PCR product
of 200 bp, permitting separation on polyacrylamide gels
of wild-type fragments from mutants carrying the 10-base tl
duplication.
Expression Analysis of Rat Csf1 Gene on a cDNA Panel. Expression
patterns and alternatively spliced variants of CSF-1 mRNA were
evaluated with a rat Multiple Tissue cDNA panel (CLON-
TECH). PCR was performed on cDNA samples to amplify either
the entire ORF, or just sequence from exons 1–3. Because of the
naturally low levels of CSF-1 transcripts, the amplified products
were separated on agarose gels, blotted, and probed with
32P-labeled rat CSF-1 cDNA.
Histology. Tibiae were dissected from tl rats, op mice, and normal
littermates at 4 weeks of age, and processed for histochemical
detection of the osteoclast enzyme tartrate-resistant acid phos-
phatase (TRAP) as described (30).
Results
Breeding Confirms tl Is a Single Gene Mutation. To map the tl locus,
we outcrossed the inbred tl strain with the inbred strain Brown
NorwaySSN. The latter was selected because it is genetically
distinct from Fischer, resulting in a high percentage of difference
in polymorphic markers (data not shown). Fig. 1 shows the
breeding scheme. Mutant males, which are able to reach sexual
maturity when husbanded under SPF conditions and fed a soft
diet, were bred with BNSSN females to produce the obligate
heterozygote F1 generation. Crossing F1 pairs yielded the F2
generation, in which the tl phenotype occurred with the expected
Mendelian frequency of about 14. The radiographs in Fig. 2
show that the tl phenotype bred true in this background,
consistent with its being the product of a single mutation and not
a strain-specific, multigene effect. A lack of marrow spaces in
long bones was evident at birth. Tooth eruption, which requires
Fig. 1. Breeding scheme. Filled symbols, mutants; open symbols, wild type;
spotted symbols, heterozygous mutants. Cosegregation of polymorphic mark-
ers and the mutation was examined in F2 animals.
Fig. 2. tl phenotype breeds true in BNSSN strain background. Radiographs
of long bones of a newborn normal rat (n) and a mutant F2 generation
littermate (tl) show high bone density and lack of marrow spaces in the mutant
(arrows). H, humerus.
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osteoclast excavation of eruption pathways through the jaws, did
not occur; and the osteopetrotic phenotype persisted for the full
2 months that we kept outcrossed mutants (not shown).
Genetic Localization of the tl Mutation. We performed genetic
analysis on 11 mutant tltl F2 animals. Markers were selected
from the rat chromosome 2 region syntenic with human chro-
mosome 1p21, where the human Csf1 gene is located (Online
Mendelian Inheritance in Man, www.ncbi.nlm.nih.goventrez
query.fcgi?dbOMIM). Homozygosity for the Fischer allele in
all affected animals was found for four of the markers analyzed
(D2Rat286, D2Mit14, D2Rat234, and D2Rat53; Fig. 3). Because
these are completely linked with the disease, a maximum LOD
score of 6.6 is obtained at recombination fraction 0. On the
proximal side the disease recombines with D2Arb15 in mutant
1, whereas on the distal side a recombination event is detected
with both D2Rat238 and D2Rat54 in mutant 3 and with
D2Rat54 in mutant 2. This refined the candidate region to 5.3
cM, flanked by the markers D2Arb15 and D2Rat238 (Fig. 3).
Based on synteny between mouse, human, and rat (Rat Genome
Database), the rat Csf1 gene is located on rat chromosome
2q34–45, between markers D2Mit14 and D2Rat 53, precisely
within the delineated candidate region (Fig. 3).
Normal Rat CSF-1 Sequence and Gene Structure. Sequencing rat
CSF-1 genomic or cDNA from both tltl and normal rats
revealed a large number of differences from the published rat
CSF-1 cDNA sequence (ref. 28; NM023981). When performing
alignments of the published nucleotide and amino acid se-
quences of normal rat and mouse (e.g., accession no.
NM007778.1) CSF-1, 100% identity was found. This 100%
identity is in fact shown in a rat vs. mouse multiple alignment in
the original publication (28). Thus, we conclude that the pub-
lished sequence is actually a misidentified mouse CSF-1 cDNA.
The sequence reported here for rat CSF-1 was obtained from
both genomic DNA and cDNA. A complete ORF of 1701 bp as
well as partial 5 and 3 UTR sequences have been deposited in
GenBank (accession no. AF515736). CSF-1 is highly conserved
between rat, mouse, and human (see Fig. 4). Identity of rat and
mouse nucleotide sequence is 91%, 86% for amino acids, with an
additional 3% conservative substitutions and two small gaps that
preserve the reading frame. The rat sequence, however, has a
unique feature: a 78-nt direct repeat after position 1380 of
the ORF. This maintains the reading frame, but inserts a
Fig. 3. Ideogram of rat chromosome 2 and genetic map of markers used to
delineate candidate region. The candidate region is shown as a gray bar on the
first vertical line. Key recombinants are given on the other vertical lines. Gray
bars represent chromosomal regions that contain the disease gene, and white
bars indicate regions that recombined and therefore cannot contain the
disease gene. The lines between represent uninformative regions. The gray
regions include Csf1.
Fig. 4. Alignment of amino acid sequences of rat, mouse, and human CSF-1 full-length ORF show high conservation. The insertion in the rat from position
476–501 of the consensus is due to a nucleotide duplication unique to the rat. Excluding this stretch, there is93% identity among the species, plus a number
of conservative substitutions. The points of tl rat and op mouse frameshifting insertions are indicated. The normal rat cDNA and amino acid sequences have been
deposited in GenBank (accession no. AF515736).
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26-aa repeat following Ala-460 in rat (Ala-474 of consensus).
Structuralfunctional implications of the repeat remain to be
determined.
We also determined the intronexon structure of the rat Csf1.
Fig. 5A shows the results of this analysis. The organization of the
rat gene is similar to mouse and human. The ORF of rat Csf1 is
divided into 8 exons split by 7 introns, spanning a genomic region
of 15 kb. The first exon contains the 5 UTR, plus the first 13
aa of the leader sequence. The remaining 19 aa of the leader
sequence are in exon 2. The translation stop signal (TAG) is in
exon 8. The sequence of exonintron boundaries and sizes of
exons and introns are given in Fig. 5B.
Identification of the tl Mutation. Sequence analyses of tl rat CSF-1,
both genomic DNA and cDNA, showed a 10-bp duplication in
exon 1 (Fig. 6A). This 10-nt sequence occurs twice in the normal
rat, but in the tl mutation it occurs three times in tandem. This
results in a frameshift mutation after codon 9 (before the signal
peptide), followed by an additional 32 unrelated amino acids and
a stop codon, thus yielding an abnormal, highly truncated
protein. As expected, the mutation was homozygous in all tltl
animals tested.
Evaluation of Alternative Splicing in Rat CSF-1 Transcripts. To un-
derstand the severity of the tl phenotype and verify that it is due
to the mutation in the amino-terminal portion of the encoded
protein, we tested whether alternatively spliced CSF-1 tran-
scripts were present in rat tissues (Fig. 7). A panel of rat tissue
cDNAs was amplified using primers spanning either the entire
CSF-1 ORF or just exons 1–3, and probed with CSF-1 cDNA.
Two transcripts were detected when the entire coding region was
amplified. Sequencing these indicated that they are consistent
with the alternatively spliced exon 6 variants seen in mouse and
human (refs. 31–34; Fig. 5). Only one band was seen for the first
3 exons, demonstrating that exon 1 is not bypassed in any
alternatively spliced CSF-1 mRNA species, and therefore that
the tl mutation prevents any functional CSF-1 from being made.
Greater Severity of Osteopetrosis in tl Rats Versus op Mice. Fig. 8
shows the virtually complete lack of osteoclasts in tl rats. In
contrast, osteoclasts are present in op mice, increasing in number
with age at some skeletal sites. TRAP-positive osteoclasts are
normally highly abundant in the tibial metaphysis at 4 weeks
postpartum. Although it can be seen that the osteoclast popu-
lation in the op mouse is markedly deficient, it is nevertheless far
greater than in the tl rat. This ability to produce osteoclasts
Fig. 5. Organization of rat Csf1 gene. (A) The ORF of the gene is dispersed
in 8 exons, shown with black boxes. 5 and 3UTRs are shown with stripes. The
alternative splice acceptor site in exon 6 is marked (asterisk). (B) Sequences of
the intronexon boundaries of the rat Csf1 gene and the length of each.
Uppercase letters, exon sequences; lowercase letters, intron sequences.
Fig. 6. The tl mutation. (A) Nucleotide and amino acid sequence of the tl CSF-1 mutation. The 10-nt repeat, underlined, commences in the third codon. It occurs
twice as a single repeat in the normal sequence, but in the tl mutation it occurs three times. The impact on the protein is seen in the translations, below, in which
the mutant sequence diverges 9 residues from the initiation Met, continues for 33 residues, and then reaches a stop codon (*). The signal sequence of the
wild-type protein, double underlined, is absent from the tl. Only the first 126 bases of the ORFs are shown. (B) Genotyping with PCR primers that flank the
mutation. After separating on a polyacrylamide gel, wild-type () fragments can be distinguished from mutants (tltl) carrying the 10-base tl duplication.
Heterozygotes (tl) clearly show two bands corresponding to the mutant and wild-type alleles.
Fig. 7. Alternative splicing of rat CSF-1 mRNA reveals no skipping of tl
mutation-containing region. CSF-1 cDNAs were amplified from rat cDNA,
separated in an agarose gel, blotted, and probed with 32P-labeled rat CSF-1
cDNA. Lanes 1–8 represent skeletal muscle, liver, kidney, lung, brain, testis,
pancreas, and heart, respectively. (A) RT-PCR product encompassing the com-
plete coding sequence of rat CSF-1. Two alternative transcripts of 0.96 and 1.91
kb, respectively, can be distinguished. The shorter fragment can be explained
by alternative splicing deletion of the major part of exon 6, as has been
described in mouse and human. (B) PCR product containing the first 3 exons
of rat CSF-1 cDNA. Only one transcript can be distinguished, indicating no
alternative splicing in the 5 part of the transcript that could bypass the tl
mutation.
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despite the op mouse frameshift mutation in CSF-1 has been
difficult to explain, particularly with the increasing body of
evidence showing that a combination of CSF-1 and TNFSF11 is
necessary and sufficient for osteoclastogenesis in vitro. Fig. 8
underscores this question, given the much more severe oste-
oclastopenia in the CSF-1 mutant tl rat.
Discussion
Mapping, sequencing, and expression results described here
define a single genetic defect in tl rats residing in the csf1 gene.
This finding is entirely consistent with all previous investigations
of tl rats, including:
1. Colony stimulating and macrophage population studies (35)
showed that postendotoxin tl rat serum lacks colony stimu-
lating activity, consistent with what was seen in op mice (36).
2. CSF-1 injections (25, 35, 37–40). The beneficial effects of
injections of CSF-1 in tl rats are well studied. They improve
some, but not all, phenotypic defects. Most amenable to
improvement are peritoneal macrophages (35), diaphyseal
and metaphyseal osteoclast populations (35, 37, 38), throm-
bocytopenia (39), and tooth eruption (35, 41). Skeletal prob-
lems unresponsive to CSF-1 injections, in particular the
metaphyseal sclerosis, growth plate chondrodystrophy, and
long bone growth (25), likely involve pathways requiring local
supply of CSF-1 in its matrix-associated or cell-bound forms,
as was suggested for certain CSF-1-resistant defects in the op
mouse (42, 43). Also, CSF-1 may be required in utero to
establish some normal cell populations, and postpartum
injections may simply come too late for benefit.
3. Stem cell transplants (21). Were the tl defect to reside in an
osteoclast-specific gene, then transplanting normal mononu-
clear precursors should restore osteoclast function and cure
the osteopetrosis. This does not happen in tl rats, and so is
consistent with the gene affected being expressed by osteo-
blasts, as CSF-1 is known to be.
4. Bone cell cocultures (19, 20). Cultured normal osteoblasts,
when stimulated by 1,25-dihydroxyvitamin D3, secrete both
CSF-1 and TNFSF11, inducing differentiation and activation
of cocultured osteoclasts. tl osteoblasts are incapable of this.
Because the tl mutation is not in TNFSF11 (26), this alone
would make CSF-1 a strong candidate for the tl mutation.
Together, all these studies support the conclusion drawn here
from our mapping, sequencing, and expression studies, that the
frameshift mutation in CSF-1 is the underlying genetic defect in
the tl rat.
The variety of phenotypic consequences of this single-gene
mutation in tl rats implies a wide-ranging activity for the encoded
protein. In addition to direct consequences of the failure of bone
resorption due to a near-complete lack of osteoclasts, other
manifestations are intriguing. tl rats exhibit abnormal angiogen-
esis at the chondroosseous junction (44); have a highly unusual,
progressive chondrodystrophy in the growth plates of endochon-
dral bones (24, 25); have disorganized actin stress fibers in
osteoblasts, accompanied by mis-sorting of -actin mRNA (45,
46); fail to switch collagen gene expression at sites of bone
growth by both endochondral and intramembranous processes
(47, 48); have retarded growth at these sites (25); and exhibit
endocrine abnormalities in vitamin D levels and decreased levels
of GH receptor and of IGF1 and its receptor (49–52).
High conservation of CSF-1 among human, rat, and mouse
implies conserved functions; nevertheless, the spectrum of phe-
notypic consequences of the tl mutation is broader and more
persistent than the other well studied CSF-1 loss-of-function
mutant, the op mouse (cf. Fig. 8). Some compensatory mecha-
nism may act in op mice that is absent from the rat model—
perhaps species or background stock differences. Hume and
Favot (53) proposed an alternative spicing event that could
bypass the exon carrying the op mutation, but whether the
translated product of the resulting message could function has
never been demonstrated. Alternatively, recent studies show a
potentially important role for VEGF in recovery of the op mouse
(54). Exploration of these and other possible mechanisms will
deepen our understanding of the biology and actions of CSF-1.
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